ClinicalTrials.gg

Program

onfekafusp alfa

Also written as “L19TNF”, “Onfekafusp alfa” and “L19TNF and TMZ”.

Its studies are mostly in Glioblastoma · Melanoma · Sarcoma · Carcinoma, Basal Cell · Glioma, led by Philogen.

Furthest: phase 3, since Oct 11, 201615 company-led studies, 12 open or runningNext primary completion: Jul 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Philogen1512 open or runningphase 3since Oct 11, 2016Feb 24, 2014Jul 2028phase 2 · NCT06284590

Also a collaborator on its studies: Merck.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Feb 24, 2014.

  1. Oct 11, 2016Phase 3 study in MelanomaNCT02938299 · 214 enrolled · France, Germany, Italy and more
  2. Jan 12, 2018Phase 2 study in LeiomyosarcomaNCT03420014 · 114 planned · United States
  3. Dec 14, 2018Phase 2 study in Glioma of BrainNCT03779230 · 20 enrolled · Switzerland
  4. Jun 28, 2019Phase 1 study in SarcomaNCT04032964 · 2 enrolled · United States
  5. Apr 17, 2020Phase 2 study in Carcinoma, Basal CellNCT04362722 · 40 planned · Germany, Poland, Switzerland
  6. Jun 17, 2020Phase 2 study in GlioblastomaNCT04443010 · 226 planned · Switzerland
  7. Sep 25, 2020Phase 2 study in GlioblastomaNCT04573192 · 142 planned · France, Germany, Italy and more
  8. Nov 25, 2020Phase 3 study in SarcomaNCT04650984 · 102 planned · France, Germany, Italy and more
  9. Jan 22, 2021Phase 2 study in SarcomaNCT04733183 · 98 enrolled · France, Germany, Italy and more
  10. Feb 24, 2022Phase 1 study in GlioblastomaNCT05304663
  11. Jan 26, 2024Phase 2 study in MelanomaNCT06284590 · 162 planned · United States, Germany, Italy
  12. Mar 4, 2024Phase 2 study in GlioblastomaNCT06336291 · 90 enrolled · United States
  13. Jul 30, 2025Phase 2 study in GliomaNCT07120984 · 52 planned
  14. Nov 7, 2025Phase 2 study in Carcinoma, Basal CellNCT07227350 · 180 planned · United States, Germany, Greece and more

Ahead

  1. Jul 2028Primary completion: phase 2 study in MelanomaNCT06284590
  2. Jan 30, 2029Primary completion: phase 2 study in GliomaNCT07120984
  3. Feb 2031Primary completion: phase 2 study in Carcinoma, Basal CellNCT07227350

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07227350Carcinoma, Basal Cell · United States, Germany, Greece and more2RecruitingFeb 2031180
NCT07120984Glioma2Not yet recruitingJan 30, 202952
NCT06336291Glioblastoma · United States2Active, not recruitingJun 202690
NCT06284590Melanoma · United States, Germany, Italy2RecruitingJul 2028162
NCT05304663Glioblastoma1WithdrawnDec 31, 20240
NCT04733183Sarcoma · France, Germany, Italy and more2Active, not recruitingDec 202598
NCT04650984Sarcoma · France, Germany, Italy and more3RecruitingDec 31, 2025102
NCT04573192Glioblastoma · France, Germany, Italy and more2RecruitingMar 2025142
NCT04443010Glioblastoma · Switzerland2RecruitingOct 2026226
NCT04362722Carcinoma, Basal Cell · Germany, Poland, Switzerland2RecruitingSep 202440
NCT04032964Sarcoma · United States1Active, not recruitingDec 20242
NCT03779230Glioma of Brain · Switzerland2CompletedJun 27, 202320
NCT03420014Leiomyosarcoma · United States2RecruitingDec 2024114
NCT02938299Melanoma · France, Germany, Italy and more3Active, not recruitingOct 2024214
NCT02076633Melanoma · Italy2CompletedMay 201521

How it is read

Names in the registry

  • “L19TNF”, 9 entries
  • “Onfekafusp alfa”, 3 entries
  • “L19TNF and TMZ”, 1 entry
  • “L19TNF and CCNU”, 1 entry
  • “L19TNF monotherapy”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
onfekafusp alfa (Philogen): development program | ClinicalTrials.gg